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Objective. To assess the eﬀect of universal screening and administration of intrapartum antibiotic prophylaxis to prevent early-
onset neonatal GBS sepsis at a private tertiary care hospital since issuance of the 2002 CDC guidelines for preventing perinatal
GBS disease. Methods. Retrospective analysis of women delivering between January 1, 2003 and December 31, 2004 at a private
tertiary care hospital in Houston, Texas. The percentage of women screened, GBS positive women receiving intrapartum antibiotic
prophylaxis, and infants developing early-onset GBS sepsis were determined. Results. 2,108 women delivered 2,135 infants with
1,874 (89%) screened for GBS. Of those screened, 1,322 (71%) tested negative and 552 (29%) tested positive for GBS. In this
analysis of 2,135 infants, 3 (0.94 cases/1,000 live births) were diagnosed with invasive GBS sepsis. Conclusion. High rates of
screening of pregnant women for GBS colonization and use of intrapartum antibiotic prophylaxis for GBS carriers can be achieved
inaprivatetertiarycarehospitalsetting.“Synopsis:HighscreeningratesforgroupBstreptococcusinaprivatetertiarycarehospital
reduce the incidence of maternal and early onset neonatal GBS infection.”
1.Introduction
Streptococcus agalactiae (group B streptococcus (GBS)) is
one of the most common bacterial causes of life-threatening
infection in newborns [1, 2]. GBS was ﬁrst reported as a
human pathogen in 1938, but it was not until the 1970s
that GBS was described as a major pathogen responsible
for neonatal sepsis, pneumonia, and meningitis [3]. GBS
neonatal infection is divided into two categories: early-
onset disease, which occurs within the ﬁrst week of life,
and late-onset infection, which occurs between one week
to 3 months of age [4]. GBS vaginal colonization occurs
in 4% to 40% of pregnant and nonpregnant women and
appears to be dependent upon geographical location [5–
9]. The GBS bacterium also may lead to chorioamnionitis,
myonecrosis of the uterus, neonatal pneumonia, premature
delivery, premature labor, premature rupture of amniotic
membranes, postpartum endometritis, and septic abortion
[10–14].Furthermore,bothmotherandnewborninfantmay
experience bacteremia, which can cause both septic shock
and death.
Prior to extensive prevention eﬀorts in the 1990s, the
incidence of invasive neonatal GBS infection ranged from
2 to 3 cases per 1,000 live births [12]. In 1996, the
Centers for Disease Control and Prevention (CDC) issued
guidelines recommending the use of intrapartum antibiotic
prophylaxis and by 1999, the incidence of early-onset GBS
infection was reduced to 0.5 cases per 1,000 live births
[12].
In2002,inordertofurtherdecreasetheincidenceofGBS
sepsis, the CDC issued revised guidelines that recommended
universal screening of pregnant women between 35 and 37
weeksofgestation[12].However,GBSinfectioncontinuesto
beaconsiderableproblem,causingsigniﬁcantmorbidityand
mortality in mothers and their newborn infants. The CDC
reported for the period 2000–2002, the average early-onset2 Infectious Diseases in Obstetrics and Gynecology
disease incidence was 0.49 cases per 1,000 live births [14].
Following the revised CDC recommendations in 2002,
average early-onset disease incidence decreased to 0.33 cases
per 1,000 live births [14].
The purpose of this retrospective study was to determine
the screening rate for GBS, the incidence of maternal
GBS colonization and early-onset neonatal GBS sepsis. In
addition, we determined compliance with the CDC recom-
mendation for the use of intrapartum antibiotic prophylaxis
for GBS positive women in a private tertiary care hospital
after the 2002 CDC recommendation for universal screening
of pregnant women for GBS colonization.
2.MaterialsandMethods
The study was conducted at The Woman’s Hospital of
Texas (WHT), Kelsey-Seybold Clinic (KSC), and the Kelsey
Research Foundation (KRF). The WHT is a private tertiary
care hospital with private physicians, a level III nursery
that accepts maternal-fetal transfers, and the only specialty
hospital in Houston, Texas focused on the care of women
and infants. Approximately 22% of all WHT deliveries each
year are high risk. KSC is a large, multispecialty medical
clinic with 300 physicians that serves an ethnically diverse
population of over 400,000 patients at 18 locations in
Houston, Texas. The KRF is a 501 (c) (3) nonproﬁt that
collaborates with healthcare and research institutions in the
Texas Medical Center to conduct health services research,
providepatient education,anddevelop qualityimprovement
initiatives.
Since 1995, the KRF has maintained a database of clinical
information from both WHT and KSC about the pregnancy
experience of over 20,000 women at KSC. The database
contains information describing the pregnancy experience
and outcomes of mothers and infants who received care at
WHT and KSC. Data for all (9) obstetricians at KSC who
routinely performed deliveries at WHT are included in this
study.
The database was queried to identify the number of
deliveries performed during the two-year period (January
1, 2003 through December 31, 2004). Outcome variables
included the number and percentage of pregnant mothers
screened for GBS, the GBS status of those women screened,
the rate of intrapartum antibiotic usage, and the incidence of
early-onsetGBSsepsis.Sepsisisdeﬁnedasapositivebloodor
spinal culture, or both, in addition to the clinical signs and
symptoms of infection. Demographic variables, including
age, ethnicity, and insurance status, also were collected
from the administrative database. Data was analyzed using
Microsoft EXCEL and ACCESS (2003, version 11.6355.6360
SP1) software. Because this is a retrospective analysis, waiver
of consent was approved by the Institutional Review Board
of WHT.
At 35 to 37 weeks gestation, a standard cotton aerobic
bacterialcultureswabwasgentlyinsertedintothelowerthird
of the vagina and then in a single motion, the perineum
was swabbed and the external anal sphincter was swabbed.
The swab was then placed in Stuart’s transport medium and
sent to the laboratory at room temperature. All specimens
were sent to a commercial laboratory as directed by patients’
insurance providers. A screening culture was completed on
arrival in labor and delivery if pregnancies were <35 weeks.
If GBS bacteriuria was diagnosed during a pregnancy, the
patient was considered colonized and treated during labor
as per the CDC guidelines [12]. All women who had GBS
positive cultures were given antibiotic prophylaxis in labor as
recommended by the CDC guidelines [12]. Mothers allergic
to penicillin were treated according to 2002 CDC guidelines
[12].
3. Results
For the two-year study period, 2,108 women delivered 2,135
infants. Of these 2,108 deliveries, 8% were less than 37 weeks
gestation. The mean gestational age at delivery was 38±2.31
weeks. There were 39 sets of twins (1.8%), 20 infant deaths
(0.9%), and 171 (8%) premature deliveries. (Prematurity
is deﬁned as infants born at a gestational age less than 37
weeks.)
The population was 40% African-American, 25% Cau-
casian, 28% Hispanic, 5% Asian, and 2% other. Approxi-
mately 3% of the women in the sample were less than 18
years of age, 56% were 18–30 years of age, 39% were 31–40
years of age, and 2% were 41 or older. The majority (71%)
of women were insured through an HMO, while 27% had
coverage with a PPO, 2% with Medicaid, and fewer than 1%
were self-insured. The demographics of mothers who were
GBS positive, GBS negative or those receiving intrapartum
antibiotic prophylaxis were comparable to the demographics
of the study sample. Chi-square tests were performed and
there were no statistical diﬀerences in the subgroups.
Among the 2,108 mothers, 1,874 (89%) were screened
for GBS and, of these, 1,322 (71%) tested negative and 552
(29%) tested positive for GBS. There were 231 (11%) of the
2,108 mothers with an unknown GBS status.
Thirty-two (1.5%) of the 2,135 infants in the sample
were evaluated for sepsis during their hospitalizations. The
sepsis workup included a CBC, blood culture, and lumbar
punctureforspinalﬂuidanalysisandculture.Gestationalage
for 21 (66%) of these infants with sepsis was <30 weeks, for 8
(25%), gestational age was 30 to 36.7 weeks, and for 3 (9%),
gestational age was ≥37 weeks. These infants were cultured
for sepsis at birth and received antibiotics until results were
available. For the majority (30) of these infants, culture
results were negative and antibiotics were discontinued. For
the two culture positive infants, one had positive blood
culturesforGBSandtheotherhadpositivebloodculturesfor
coagulase negative staphylococci, and none had meningitis.
Thirty-one of the 32 (97%) infants were admitted to the
NICU and had admissions of more than 30 days. Of these
infants, one developed GBS sepsis.
Of the 1,322 mothers who tested negative for GBS,
346 (26%) received antibiotic prophylaxis. Of the 346 that
received antibiotics, 314 (91%) received antibiotics for surgi-
cal prophylaxis (C-section) and 32 (9%) received antibiotics
for acute infection (chorioamnionitis, pyelonephritis, andInfectious Diseases in Obstetrics and Gynecology 3
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respiratory infection). Among the 314 women who received
antibiotics for surgical prophylaxis, 43 (14%) delivered
vaginally. Interestingly, these 43 women, although initially
GBS negative by culture at 35–37 weeks, met the CDC risk-
based criteria for GBS prophylaxis when admitted to labor
and delivery.
A total of 523 (95%) of the 552 mothers who were
GBS positive received intrapartum antibiotic prophylaxis.
The three GBS positive infants were born to GBS positive
mothers and all three had a gestational age <36 weeks
(33.5, 32.5, and 25.2 weeks). The mother who delivered
her baby at 33.5 weeks had severe chorioamnionitis with
artiﬁcial rupture of membranes and delivered vaginally
on the day she was admitted. She received prophylactic
ampicillin and subsequently tested positive for GBS. The
second mother delivered twins at 32.5 weeks by repeat C-
section on the day she was admitted. The mother had
premature rupture of membranes with GBS status unknown
at time of delivery and subsequently tested positive for GBS.
One twin was GBS positive and had intrauterine growth
retardation(IUGR).ThethirdGBSpositivemotherdelivered
her baby at 25.2 weeks by primary C-section. The mother
was admitted eight days prior to delivery and diagnosed with
preterm premature rupture of membranes, and chorioam-
nionitis.Shereceivedampicillin/sulbactam,Amoxicillin,and
Erythromycin antepartum, and Cefazolin at the time the
umbilical cord was clamped. The infant, in addition to being
GBS positive with bacteremia, subsequently was diagnosed
withKlebsiellapneumoniaandexpired14daysafterdelivery.
A total of 165 (71%) of the 231 mothers with unknown
GBS status received antibiotic prophylaxis for GBS based on
weakriskfactorassessment.Ofthese165mothers,106(64%)
delivered babies at <37 weeks gestational age, 1 (0.9%) had
rupture of membrane with labor >18 hours, there were no
mothers in this group with a temperature >38◦C, and 105
(99%) had no recognized risk factors as outlined in the CDC
guidelines [12] except for unknown GBS status. The ﬂow
diagram in Figure 1 shows the status of the women in the
study.
4. Discussion
Our study demonstrates that in a private tertiary care
hospital setting, both a high rate of screening for GBS
and administration of intrapartum antibiotic prophylaxis
can be achieved. No infants ≥37 weeks gestation developed
invasive GBS disease. The three infants with early-onset
GBS sepsis born to GBS positive mothers were less than 34
weeks gestation, and they would have been treated based on
risk factors alone. The results for this study population are
reﬂective of the overall population delivering at WHT.4 Infectious Diseases in Obstetrics and Gynecology
A major strength of this study is our ability to capture
data on GBS screening and usage of intrapartum antibiotic
prophylaxis from our obstetrical database. Similar surveil-
lance studies conducted by the CDC have been limited due
to their inability to measure health care provider compliance
with screening guidelines [14]. Despite our high rate of
GBS screening, 11% of mothers had unknown GBS status
at delivery. However, more than two-thirds of these women
received prophylaxis for GBS based on risk factors alone. An
additional strength is that the results reﬂect the management
of GBS in a private tertiary care nonteaching obstetrical unit,
with80practicingobstetricians,versusanacademichospital.
The widely diverse nonhomogeneous patient population
speaks to the nondiscriminatory nature of GBS colonization.
The retrospective nature of the study may be a weakness
because the study sample was not controlled and was
limited to a small proportion of the total deliveries at WHT.
However, the study sample did represent 42% of all KSC
deliveries during the two-year study period.
Another weakness is that there were 11% (231) of moth-
ers that were either not screened or data were not available. If
aGBSpositiverateof29%isused,thenthiswouldcontribute
an additional 70 women to the GBS positive group.
A confounding ﬁnding was that there were three
newborns who developed early-onset GBS sepsis born to
GBS positive mothers that were administered appropriate
intrapartum antibiotic prophylaxis. It is not known whether
or not GBS amnionitis was present at the time of admission
to labor and delivery. None of these women had clinical
signs or symptoms of infection. This emphasizes the fact that
universal screening and intrapartum antibiotic prophylaxis
cannot eliminate the occurrence of neonatal early-onset GBS
sepsis.
Based on our experience reviewing GBS in mothers, we
have undertaken an extensive review of neonatal outcomes
in newborns of mothers receiving antibiotic prophylaxis
within 4 hours of delivery. We also are developing a study to
determine whether rapid screening using the PCR method in
untested and GBS negative mothers will further reduce GBS
infection in newborns.
5. Conclusion
This study found that adherence to the 2002 CDC guidelines
for screening and prophylaxis for GBS could readily be
accepted, and that in the ﬁrst year of implementation, 89%
of women delivering in a private tertiary care hospital with a
large number of practicing obstetricians were screened. This
retrospectivestudydemonstratedthatuniversalscreeningfor
GBS is eﬀective and can be achieved in a private tertiary care
hospital.
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